Metrics to compare | FLUIC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipFLUICPeersSector | |
|---|---|---|---|---|
P/E Ratio | −30.4x | 23.1x | −0.5x | |
PEG Ratio | −0.39 | 0.45 | 0.00 | |
Price/Book | 5.0x | 2.4x | 2.6x | |
Price / LTM Sales | 3.5x | 4.5x | 3.1x | |
Upside (Analyst Target) | - | 0.0% | 53.4% | |
Fair Value Upside | Unlock | 5.5% | 7.1% | Unlock |
Fluicell AB (publ), a life science company, develops and provides clay instruments for 3D bioprinting and cell analysis and flow control on single-cell level in Sweden. The company offers BIOPEN, a powerful tool for high precision cell biology that uses open volume microfluidics; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve system, an ion channel screening platform, which allows to record various ion channel current in patch clamp recording configuration. It also provides Biopixlar, a 3D single-cell bioprinting platform that produces single cell arrays to organoids and complex tissues; Nexocyte, a platform for universal tissue production; and Biopixlar AER, a single-cell bioprinting platform that fits into a biosafety cabinet. Fluicell AB (publ) was incorporated in 2012 and is based in Mölndal, Sweden.